GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart ...

The Food and Drug Administration (FDA) has approved Optison ™ (perflutren protein-type A microsphere) injectable suspension for use in pediatric patients with suboptimal echocardiograms to opacify the ...

The Wall Street veteran's technical analysis of natural gas helped members capture gains on UNG calls. His recent alert ...

GE HealthCare (GEHC) announced the FDA has approved a pediatric indication for its Optison ultrasound enhancing agent. This approval will help improve the clarity of echocardiograms for diagnosing ...

GE HealthCare Technologies Inc. GEHC recently announced FDA approval for Optison, its polyethylene glycol (PEG)-free ultrasound enhancing agent, for use in pediatric patients. This milestone ...

(RTTNews) - GE HealthCare (GEHC) announced Tuesday the U.S. Food and Drug Administration (FDA) has approved a pediatric indication for the company's Optison (Perflutren Protein-Type A Microspheres ...

The latest approval will help provide clearer echocardiogram images for cardiologists to diagnose heart conditions in pediatric patients Optison is the only polyethylene glycol (PEG)-free ...

The U.S. FDA has approved GE HealthCare’s Optison™ (Perflutren Protein-Type A Microspheres Injectable Suspension, USP) ultrasound enhancing agent for use in pediatric patients. The latest approval ...